Evidence map›Paper›PMID 40201451›Full record

ReviewBiotechnology reports (Amsterdam, Netherlands)2025

Exploring the multifaceted roles of resuscitation-promoting factors in tuberculosis: Implications for diagnosis, vaccine development, and drug targeting.

Gamze Tanriver, Salman Ali Khan, Artur Góra, Novel N Chegou, Shima Mahmoudi

Abstract readReview
In one paragraph

Review in Biotechnology reports (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gamze TanriverTunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice 44-100, Poland.
Salman Ali KhanTunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice 44-100, Poland.
Artur GóraTunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice 44-100, Poland.
Novel N ChegouSouth African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town 8000, South Africa.
Shima MahmoudiBiotechnology Centre, Silesian University of Technology, Krzywoustego 8, Gliwice 44-100, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a significant global health challenge, necessitating continued research efforts to unravel its complex pathogenesis and advance diagnostic, therapeutic, and preventive strategies. Resuscitation-promoting factors (Rpfs) are peptidoglycan-hydrolyzing enzymes that have gained attention due to their key roles in TB infection dynamics. This review aims to provide a comprehensive overview of Rpfs in TB, highlighting their immunological roles, diagnostic potential, and implications for vaccine development and drug targeting through both in silico and experimental approaches. Rpfs exhibit diverse roles in TB, influencing bacterial resuscitation from dormancy, and immune modulation through interactions with host immune cells, such as dendritic cells, and they are potential targets for novel diagnostic and therapeutic interventions. Their ability to stimulate immune responses, particularly interferon-γ production by T cells, underscores their potential as vaccine candidates against TB. Moreover, Rpfs represent promising targets for drug discovery, with inhibitors potentially disrupting bacterial resuscitation and growth.

Indexed as

DiagnosisDrug targetResuscitation-promoting factors (Rpfs)TuberculosisVaccine development

Identifiers

PMID40201451
PMCPMC11978375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.